MCM
TRVI icon

MAI Capital Management’s Trevi Therapeutics TRVI Stock Holding History

MAI Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
56,130
-8,995
-14% -$131K ﹤0.01% 951
2026
Q1 		$777K Sell
65,125
-12,644
-16% -$142K ﹤0.01% 860
2025
Q4 		$974K Sell
77,769
-20,723
-21% -$239K 0.01% 744
2025
Q3 		$901K Sell
98,492
-749,061
-88% -$5.62M 0.01% 740
2025
Q2 		$4.64M Sell
847,553
-537,497
-39% -$3.34M 0.03% 344
2025
Q1 		$8.71M Buy
1,385,050
+28,164
+2% +$134K 0.07% 243
2024
Q4 		$5.59M Buy
1,356,886
+29,601
+2% +$94.8K 0.04% 312
2024
Q3 		$4.43M Buy
1,327,285
+8,789
+0.7% +$26.1K 0.04% 273
2024
Q2 		$3.93M Buy
1,318,496
+186,675
+16% +$519K 0.04% 293
2024
Q1 		$3.9M Sell
1,131,821
-147,637
-12% -$329K 0.04% 287
2023
Q4 		$1.71M Sell
1,279,458
-171,942
-12% -$260K 0.02% 351
2023
Q3 		$3.16M Sell
1,451,400
-83,252
-5% -$188K 0.05% 238
2023
Q2 		$3.67M Sell
1,534,652
-65,763
-4% -$166K 0.05% 221
2023
Q1 		$2.96M Sell
1,600,415
-120,261
-7% -$272K 0.05% 237
2022
Q4 		$3.32M Sell
1,720,676
-298,488
-15% -$588K 0.06% 216
2022
Q3 		$3.11M Sell
2,019,164
-20,845
-1% -$68.3K 0.06% 210
2022
Q2 		$5.73M Buy
2,040,009
+498,538
+32% +$1.22M 0.11% 150
2022
Q1 		$3.39M Buy
+1,541,471
New +$1.6M 0.06% 194

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

MAI Capital Management's TRVI Position: Q2 2026 in Review

MAI Capital Management reduced its Trevi Therapeutics (TRVI) stake by 14% in Q2 2026, selling an estimated $131K and leaving 56,130 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #951.

MAI Capital Management first reported a position in TRVI in Q1 2022 and has held it in 18 quarters since. The position peaked at $8.71M in Q1 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • MAI Capital Management held 56,130 shares of Trevi Therapeutics worth $1.05M as of Q2 2026.
  • MAI Capital Management sold 8,995 Trevi Therapeutics shares in Q2 2026, an estimated $131K.
  • Trevi Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #951 holding.
  • MAI Capital Management first reported a position in Trevi Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • MAI Capital Management's Trevi Therapeutics position peaked at $8.71M in Q1 2025.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.